Valuation: Orexo AB

Market Cap 532M 54.87M 48.19M 44.82M 41.13M 77.27M 5.28B 78.47M 208M 2.6B 206M 202M 8.98B P/E 2026 *
-1.46x
P/E 2027 * -2.09x
Enterprise Value 427M 44.05M 38.68M 35.98M 33.01M 62.03M 4.24B 62.98M 167M 2.09B 165M 162M 7.21B EV / Sales 2026 *
22.5x
EV / Sales 2027 * 14.2x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day+0.26%
1 week-1.55%
Current month-36.50%
1 month-32.42%
3 months-24.55%
6 months-52.60%
Current year-49.37%
1 week 14.04
Extreme 14.04
16.76
1 month 14.04
Extreme 14.04
25.45
Current year 14.04
Extreme 14.04
36
1 year 14.04
Extreme 14.04
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap.
9/4/25 Free

Chief Executive Officer

1,393 0.0040%
9/4/25 Buy

Chief Executive Officer

6 0.0000%
9/3/25 Free 149 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+0.26%-1.55%-27.60%-13.51% 54.87M
+0.45%+2.80%+55.83%+20.48% 324B
-0.07%+2.09%+22.76%-11.68% 68.88B
+1.35%+5.29%+39.41%+91.60% 9.72B
+0.93%-1.38%+1.71%-4.10% 8.37B
+1.13%+1.51%-20.98%-4.73% 4.32B
-4.00%+0.71%-7.10%+12.39% 3.62B
+4.90%+5.79%-39.25%+19.34% 3.83B
-2.10%-3.83%+40.64%+53.74% 2.68B
-4.07%-2.45%-3.76%-17.52% 2.04B
Average -0.12%+0.96%+6.16%+14.60% 42.72B
Weighted average by Cap. +0.37%+2.17%+46.51%+16.12%

Financials

2026 *2027 *
Net sales 19M 1.96M 1.72M 1.6M 1.47M 2.76M 189M 2.8M 7.42M 92.74M 7.35M 7.2M 321M 27.5M 2.84M 2.49M 2.32M 2.13M 3.99M 273M 4.05M 10.74M 134M 10.64M 10.41M 464M
Net income -375M -38.66M -33.96M -31.58M -28.98M -54.45M -3.72B -55.29M -147M -1.83B -145M -142M -6.33B -270M -27.89M -24.49M -22.78M -20.9M -39.28M -2.69B -39.88M -106M -1.32B -105M -102M -4.57B
Net Debt -105M -10.83M -9.51M -8.84M -8.11M -15.25M -1.04B -15.48M -41.02M -513M -40.64M -39.76M -1.77B -143M -14.74M -12.95M -12.04M -11.05M -20.76M -1.42B -21.08M -55.87M -698M -55.35M -54.15M -2.41B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
26-07-24 SEK 15.24 +0.26% 15,640
26-07-23 SEK 15.20 -1.17% 41,617
26-07-22 SEK 15.38 -1.41% 45,380
26-07-21 SEK 15.60 -5.34% 34,140
26-07-20 SEK 16.48 +6.46% 55,835
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise